| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10032762 | HBV | ENSG00000163399.16 | protein_coding | ATP1A1 | Yes | Yes | 476 | P05023 |
| TVIS10059189 | HBV | ENSG00000163399.16 | protein_coding | ATP1A1 | Yes | Yes | 476 | P05023 |
| TVIS30014568 | HIV | ENSG00000163399.16 | protein_coding | ATP1A1 | Yes | Yes | 476 | P05023 |
| TVIS30077154 | HIV | ENSG00000163399.16 | protein_coding | ATP1A1 | Yes | Yes | 476 | P05023 |
| TVIS30024844 | HIV | ENSG00000163399.16 | protein_coding | ATP1A1 | Yes | Yes | 476 | P05023 |
| TVIS20068134 | HPV | ENSG00000163399.16 | protein_coding | ATP1A1 | Yes | Yes | 476 | P05023 |
| TVIS44007688 | HTLV-1 | ENSG00000163399.16 | protein_coding | ATP1A1 | Yes | Yes | 476 | P05023 |
| TVIS43000129 | MCV | ENSG00000163399.16 | protein_coding | ATP1A1 | Yes | Yes | 476 | P05023 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ATP1A1 |
|---|---|
| DrugBank ID | DB01378 |
| Drug Name | Magnesium cation |
| Target ID | BE0000732 |
| UniProt ID | P05023 |
| Regulation Type | |
| PubMed IDs | 16808357; 16928192; 16990961; 17294093 |
| Citations | Buchachenko AL, Kuznetsov DA, Berdinskii VL: [New mechanisms of biological effects of electromagnetic fields]. Biofizika. 2006 May-Jun;51(3):545-52.@@Sirijovski N, Olsson U, Lundqvist J, Al-Karadaghi S, Willows RD, Hansson M: ATPase activity associated with the magnesium chelatase H-subunit of the chlorophyll biosynthetic pathway is an artefact. Biochem J. 2006 Dec 15;400(3):477-84.@@Balasubramaniyan V, Nalini N: Leptin alters brain adenosine triphosphatase activity in ethanol-mediated neurotoxicity in mice. Singapore Med J. 2006 Oct;47(10):864-8.@@Nogovitsina OR, Levitina EV: Neurological aspects of the clinical features, pathophysiology, and corrections of impairments in attention deficit hyperactivity disorder. Neurosci Behav Physiol. 2007 Mar;37(3):199-202. |
| Groups | Approved; Nutraceutical |
| Direct Classification | Homogeneous alkaline earth metal compounds |
| SMILES | [Mg++] |
| Pathways | Cerivastatin Action Pathway; Ethylmalonic Encephalopathy; Arachidonic Acid Metabolism; Short-Chain Acyl-CoA Dehydrogenase Deficiency (SCAD Deficiency); Oxaprozin Action Pathway; Oxidation of Branched-Chain Fatty Acids; Fructose and Mannose Degradation; Phenylacetate Metabolism; Mefenamic Acid Action Pathway; Bromfenac Action Pathway; Riboflavin Metabolism; Amino Sugar Metabolism; Naproxen Action Pathway; Glycolysis; Sphingolipid Metabolism; Hypercholesterolemia; Xanthine Dehydrogenase Deficiency (Xanthinuria); Meloxicam Action Pathway; S-Adenosylhomocysteine (SAH) Hydrolase Deficiency; Glutaric Aciduria Type I; Phenylketonuria; Glycine N-Methyltransferase Deficiency; Ketorolac Action Pathway; Dimethylglycine Dehydrogenase Deficiency; Acetylsalicylic Acid Action Pathway; Lovastatin Action Pathway; Nucleotide Sugars Metabolism; Dihydropyrimidine Dehydrogenase Deficiency (DHPD); Folate Metabolism; Adenylosuccinate Lyase Deficiency |
| PharmGKB | PA164712884 |
| ChEMBL |
